linjc16/ctgov huggingface dataset:
A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to provide the physicians with quality long term follow up data on subjects from the Breast Cancer Clinic and the Plastic Surgery Clinic who have been newly diagnosed with breast cancer and will receive treatment for the cancer at this facility. Over the last two decades many studies have been done concerning the quality of life after a mastectomy and/or reconstruction process. The majority of these studies only run for one year post reconstruction, some however, do include a two year follow up. The investigators are proposing a 5 year long term follow up study on subjects who will be diagnosed and treated here at the Breast Cancer Clinic and the Plastic Surgery Clinic. The investigators first questionnaire will be given prior to any treatment for breast cancer, giving us a baseline for the subject's current quality of life. At each successive year, the subject will be given another questionnaire with regards to their progression through the reconstructive process. At the end of 5 years, the subject will complete a final questionnaire. These questionnaires will deal with many areas of daily life functions; activities of daily living, anxiety, depression, social interactions, personal and sexual relationships.

Detailed Description
-----------------
Upon informed consent of subject, a baseline questionnaire will be completed by the subject. At years 1, 2, 3, and 4 follow up questionnaires will be sent for completion to the subject. At year 5 a final questionnaire will be sent to the subject for completion.After all subjects have completed the study, data will be sent to the Department of Biostatics for analysis.

Official Title
-----------------
A Prospective Study on Newly Diagnosed Breast Cancer Patients: A 5 Year Follow Up on Quality of Life

Conditions
-----------------
Newly Diagnosed Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any female age 18 or over that has been diagnosed with breast cancer and has been treated and followed in the Breast Cancer Clinic and the Plastic Surgery Clinic is eligible for study participation. Exclusion Criteria: Any person not meeting these requirements will not be eligible for study participation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Cancer Quality of Life Survey
Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain

Study Overview
=================
Brief Summary
-----------------
Patients with endometriosis-associated pain have conservative surgery performed to remove all visible lesions. Then, patients are randomized into two groups. In the first group patients have depot medroxyprogesterone acetate injections every 3 months for a total of 6 months.In the second group patients have oral contraceptive combined pills everyday for 6 months. Patients are followed up on recurrence of pain for 1 year after medication.

Official Title
-----------------
Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial.

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Drug: intramuscular depot medroxyprogesterone acetate
* Drug: ethinyl estradiol 30 micrograms, gestodene 75 micrograms


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premenopausal women from 18 to 45 years of age with endometriosis-associated pain for at least 6 months who had conservative surgery performed. Exclusion Criteria: Medical therapies for endometriosis other than NSAID within previous 6 months Contraindication to the drugs Wish to conceive Request for extirpative surgery Other pelvic pathology ( adenomyosis, chronic PID, submucous myoma uteri )

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Intramuscular depot medroxyprogesterone acetate | Drug: intramuscular depot medroxyprogesterone acetate<br>* 150 mg, Intramuscular, every 3 months<br>* Other names: Depo Provera;|
| Active Comparator: B<br>ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms | Drug: ethinyl estradiol 30 micrograms, gestodene 75 micrograms<br>* one tablet orally, everyday<br>* Other names: Gynera;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' satisfaction with the treatment |  | 1 year and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain reduction and adverse side effects |  | 1 year and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pelvic pain, postoperative, medical therapy
The Role of SNP of ECM and MMP on the Development of Pathological High Myopia

Study Overview
=================
Brief Summary
-----------------
To study the clinical characteristics and inheritance of pathological myopia in Taiwanese patients.

Detailed Description
-----------------
High myopia (pathological myopia) is caused by excessive axial elongation that primarily involves the ora-equatorial area and the posterior pole. Pathological myopia often accompanied by glaucoma, cataracts, macular degeneration, and retinal detachment, leading to blindness when the damage to the retina is extremely severe. Population and family studies in Chinese have provided evidence for a geneticcomponent to pathologic myopia. Children of myopic parents are more likely to have myopia than are children of nonmyopic parents. Therefore, it is possible to search a potential candidate gene for myopia through the genomic study of pathological myopia. The retina receives the signal from the retina-RPE complexes and affects the growth of scleral coats. The changes of scleral components, collagen fibrils and proteoglycans, are noted in experimental and human myopia and induce the pathology of high myopia. It is interesting to know that individual difference of SNP in the components of scleral coat affects the response to the signal from retina-RPE complexes. The most important effectors in scleral coats are collagens, proteoglycans, MMPs and TIMPs. Therefore, the difference of SNPs in different genes might contribute the formation of scleral thinning during myopia development. In this project, we will focus on this subject by using GenomeLab SNPstream Genotyping System which is powerful and helpful for identify some specific SNPs in the regard.

Official Title
-----------------
National Taiwan University Hospital

Conditions
-----------------
Myopia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: They are unrelated Chinese subjects with high myopia ≦-6.00D. The diagnosis of myopia is determined by the refractive error. Anisometropic individuals, with a refractive error of ≦-6.00 D for one eye and ≦-6.00 D for the other eye, with at least a 2-D difference between the two eyes, are considered unaffected Exclusion Criteria: Individuals are excluded if there is known ocular disease or insult that could predispose to myopia, such as retinopathy of prematurity or early-age media opacification, or if they had a known genetic disease associated with myopia, such as Stickler or Marfan syndrome.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
high myopia, genomic
A Study of the Immune Response to Heplisav in Healthy Older Adults

Study Overview
=================
Brief Summary
-----------------
This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.

Detailed Description
-----------------
The purpose of this study is to examine how the immune system responds to vaccination with HEPLISAV.

Official Title
-----------------
A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.

Conditions
-----------------
Hepatitis B

Intervention / Treatment
-----------------
* Biological: HEPLISAV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50 to 70 years of age, inclusive In good health in the opinion of the principal investigator, based upon medical history and physical examination Serum negative for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) If female of childbearing potential, agree to consistently use a highly effective method of birth control from the screening visit through Week 12/Visit 10 Exclusion Criteria: Pregnant, breastfeeding, or planning a pregnancy Known history of an autoimmune disease Previously received any hepatitis B vaccine (approved or investigational) Body-mass index (BMI) >30 kg/m2, diabetes mellitus (type 1 or 2), or other chronic medical condition that in the opinion of the principal investigator might interfere with the immune response to hepatitis B vaccination

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HEPLISAV<br> | Biological: HEPLISAV<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the changes in cellular responses and gene expression patterns in serial blood samples collected from healthy older adults after vaccination with HEPLISAV. |  | Day 1, 3, and 7 and on Day 28 | 
| Determine which of these changes correlate with the development of protective levels of antibody (anti-HBs >/= 10 milli-international unit (mIU)/mL) to hepatitis B virus (HBV). |  | Day 1, 3, and 7 and on Day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heplisav
Direct Laryngoscopy During Cervical Trauma

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare time, success rates of different laryngoscope blades for intubation with an immobilized cervical spine in a standardized pediatric manikin model.

Official Title
-----------------
Comparison Three Different Laryngoscope Blades for Endotracheal Intubation in Pediatric Patients With Cervical Spine Immobilization.

Conditions
-----------------
Trauma

Intervention / Treatment
-----------------
* Device: MIL
* Device: MAC
* Device: McCoy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: give voluntary consent to participate in the study minimum 1 year of work experience in emergency medicine experienced emergency medicine personnel (physicians, nurses, paramedics) Exclusion Criteria: not meet the above criteria wrist or low back diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intubation with immobilized cervical spine<br>endotracheal intubation with immobilized cervical spine | Device: MIL<br>* Direct laryngoscopy. Laryngoscopy with Miller blade<br>Device: MAC<br>* Direct laryngoscopy. Laryngoscopy with Macintosh blade<br>Device: McCoy<br>* Direct laryngoscopy. Laryngoscopy with McCoy blade<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of intubation | effectiveness of first, second and third intubation attempts and overall effectiveness of intubation by participants | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intubation time | time in seconds required for a successful intubation attempt | 1 day | 
| Cormack-Lehane grading | self-reported percentage the vocal cord visualization using the Cormack-Lehane grading (grade 1-4) | 1 day | 
| Preferred ETI device | participants were asked which method of ETI they would prefer in a real-life resuscitation. | 1day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation
Topical CBD for Musculoskeletal Pain

Study Overview
=================
Brief Summary
-----------------
Various OTC and CBD containing topicals are evaluated in a double blind survey. Each sample has a QR code that is to be scanned before applying. The QR code links to a survey form with application instructions and collects participant information and feedback.

Official Title
-----------------
Immediate Effect of Topical CBD for Musculoskeletal Pain

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: GoodFOR Pain
* Drug: Icy Hot
* Drug: Tiger Balm
* Drug: Bengay
* Drug: CBD Clinic Muscle and Joint Pain Relief Ointment
* Drug: CBD FX CBD Muscle and Joint Cream: Cooling Formula
* Drug: Essential Wholesale Muscle Gel
* Drug: Extract Labs Muscle Cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: has Pain Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: Individuals are provided with a sample of topical substance to apply to a localized region of pain.
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.|
|Drug: Icy Hot|a FDA OTC registered topical analgesic.|
|Drug: Tiger Balm|a FDA OTC registered topical analgesic|
|Drug: Bengay|a FDA OTC registered topical analgesic.|
|Drug: CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.|
|Drug: CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.|
|Drug: Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.|
|Drug: Extract Labs Muscle Cream|a non FDA registered topical analgesic.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Before/After Application | McGill Pain Questionnaire | 5 min post intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficiency | Time and Duration of Pain Relief | 5 min post intervention |
Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the prevalence of dry eye disease in patients diagnosed with rheumatoid arthritis. No treatment is administered in this study.

Detailed Description
-----------------
We investigated the prevalence of dry eye disease in patients diagnosed with rheumatoid arthritis by information sheets and direct recruitment of patients of potential study participants diagnosed with rheumatoid arthritis. Subjective assessment for dry eye disease was performed using Ocular Surface Disease Index (OSDI) questionnaire. The following objective tests of dry eye disease were employed: tear osmolarity (TO), tear break-up time (TBUT), corneal fluorescein staining score and conjunctival lissamine green staining scores using the National Eye Institute-recommended grading system, and Schirmer without anesthetic. The Dry Eye Severity Grading Scheme highlighted by the Dry Eye WorkShop was adapted to quantify dry eye disease severity level.

Official Title
-----------------
Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis

Conditions
-----------------
Dry Eye Syndromes, Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with rheumatoid arthritis 18 years old or older Speaks and understands English and/or Spanish Exclusion Criteria: Unable to provide consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry eye disease, rheumatoid arthritis
The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema

Study Overview
=================
Brief Summary
-----------------
Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema. In some patients, CME persists even after inflammation control, and additional treatment is needed for better vision. Oral steroid, periocular and intravitreal Triamcinolone are the principles in treatment, but some complications like cataracts and increased ocular pressure have been seen. Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular endothelial growth factor (VEGF) inhibition. In this study, the investigators are going to compare the therapeutic affect of intravitreal Diclophenac and Triamcinolone in persistent uveitic cystoids macular edema. Since diclophenac is a cheap and accessible drug in all curative centers it could be applied instead of Triamcinolone.

Official Title
-----------------
The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema

Conditions
-----------------
Uveitis, Cystoid Macular Edema

Intervention / Treatment
-----------------
* Drug: Diclophenac
* Drug: Triamcinolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cystoids macular edema which is diagnosed by OCT and flurocein angiography 5/200 < Visual acuity < 20/50 resistance to routine treatment (oral treatment, periocular injection) Exclusion Criteria: history of retinal disease cause macular edema like diabetes arterial occlusion monocular patients patients candidate for intra-ocular operation history of glaucoma or ocular hypertension any cataract that would interfere with OCT
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diclophenac<br> | Drug: Diclophenac<br> <br> |
| Experimental: Triamcinolone<br> | Drug: Triamcinolone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |